Clinical Trial Update: Efficacy and Tolerance of Cellularised LG002 Versus Uncellularised LG002 in the Treatment of Severe Burns Injuries [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing cellularised LG002 to uncellularised LG002 for severe burns, reporting on efficacy and tolerability; the study status is termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burns

Drugs mentioned

• LG002 (uncellularised)
• LG002 cellularised

Snippet

Sponsor: Laboratoires Genévrier | Conditions: Burns | Phase 2 | Status: TERMINATED